Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $33.25 million versus the consensus estimate of $32.42 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.